Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Oligometastatic Non-small Cell Lung Cancer (NSCLC) 1Neoplasms 1Laparoscopy 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Minimally Invasive Surgical Procedures × Clear all
NCT02463877 2022-09-14

A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy

University of California, San Diego

Phase 2 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡